StocksFundsScreenerSectorsWatchlists
CDNA

CDNA - CareDx Inc Stock Price, Fair Value and News

8.21USD-0.32 (-3.75%)Market Closed

Market Summary

CDNA
USD8.21-0.32
Market Closed
-3.75%

CDNA Stock Price

View Fullscreen

CDNA RSI Chart

CDNA Valuation

Market Cap

425.1M

Price/Earnings (Trailing)

-2.23

Price/Sales (Trailing)

1.52

EV/EBITDA

-1.95

Price/Free Cashflow

-23.12

CDNA Price/Sales (Trailing)

CDNA Profitability

Operating Margin

81.58%

EBT Margin

-67.83%

Return on Equity

-72.81%

Return on Assets

-40.76%

Free Cashflow Yield

-4.33%

CDNA Fundamentals

CDNA Revenue

Revenue (TTM)

280.3M

Rev. Growth (Yr)

-20.41%

Rev. Growth (Qtr)

-2.42%

CDNA Earnings

Earnings (TTM)

-190.3M

Earnings Growth (Yr)

-544.32%

Earnings Growth (Qtr)

-402.86%

Breaking Down CDNA Revenue

Last 7 days

-13.8%

Last 30 days

-19.0%

Last 90 days

-22.5%

Trailing 12 Months

-7.5%

How does CDNA drawdown profile look like?

CDNA Financial Health

Current Ratio

4.02

CDNA Investor Care

Buy Backs (1Y)

3.53%

Diluted EPS (TTM)

-3.54

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023319.6M309.3M297.1M280.3M
2022308.4M314.9M318.6M321.8M
2021221.2M253.6M275.8M296.4M
2020139.5M149.8M169.4M192.2M
201988.5M102.1M114.8M127.1M
201850.8M56.6M65.6M76.6M
201745.7M47.0M46.7M48.3M
201627.5M31.1M36.4M40.6M
201528.6M29.0M29.4M28.1M
201423.0M24.4M25.2M27.3M
201320.9M21.3M21.7M22.1M
201200020.5M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of CareDx Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 08, 2024
jain abhishek
sold (taxes)
-2,239
9.53
-235
chief financial officer
Apr 04, 2024
maag peter
acquired
-
-
1,249
-
Apr 04, 2024
goldberg michael
acquired
-
-
3,686
-
Feb 05, 2024
johnson alexander l
sold (taxes)
-9,587
8.56
-1,120
see remarks
Feb 02, 2024
johnson alexander l
sold (taxes)
-36,327
8.72
-4,166
see remarks
Feb 01, 2024
jain abhishek
sold (taxes)
-101,845
8.88
-11,469
chief financial officer
Feb 01, 2024
jain abhishek
acquired
-
-
174,520
chief financial officer
Feb 01, 2024
johnson alexander l
sold (taxes)
-99,855
8.88
-11,245
see remarks
Feb 01, 2024
johnson alexander l
acquired
-
-
174,520
see remarks
Jan 29, 2024
johnson alexander l
sold (taxes)
-11,065
9.88
-1,120
see remarks

1–10 of 50

Which funds bought or sold CDNA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 12, 2024
HARBOR INVESTMENT ADVISORY, LLC
unchanged
-
-564
4,236
-%
Apr 11, 2024
ARMSTRONG HENRY H ASSOCIATES INC
unchanged
-
-22,610
169,822
0.02%
Apr 05, 2024
CWM, LLC
added
2,095
14,000
15,000
-%
Apr 05, 2024
GAMMA Investing LLC
added
27.92
768
2,086
-%
Apr 05, 2024
LOS ANGELES CAPITAL MANAGEMENT LLC
added
9.23
-102,496
2,742,880
0.01%
Mar 28, 2024
Newbridge Financial Services Group, Inc.
unchanged
-
7,500
18,000
0.01%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-99.42
-15,594
156
-%
Mar 11, 2024
VANGUARD GROUP INC
reduced
-0.46
20,466,000
49,436,200
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
47.88
6,818,110
11,259,400
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
128,630
310,476
-%

1–10 of 49

Are Funds Buying or Selling CDNA?

Are funds buying CDNA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CDNA
No. of Funds

Unveiling CareDx Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
arrowmark colorado holdings llc
0%
0
SC 13G/A
Feb 13, 2024
bellevue asset management (uk) ltd.
7.3%
3,954,792
SC 13G/A
Feb 13, 2024
gagnon securities llc
4.7%
2,518,484
SC 13G/A
Feb 13, 2024
vanguard group inc
7.62%
4,119,682
SC 13G/A
Feb 12, 2024
nikko asset management americas, inc.
5.31%
2,874,899
SC 13G
Feb 05, 2024
sumitomo mitsui trust holdings, inc.
5.31%
2,874,899
SC 13G
Jan 29, 2024
ark investment management llc
13.30%
7,194,722
SC 13G/A
Jan 24, 2024
blackrock inc.
10.2%
5,543,666
SC 13G/A
Jan 10, 2024
state street corp
5.17%
2,796,267
SC 13G/A
Jul 07, 2023
blackrock inc.
10.1%
5,439,512
SC 13G/A

Recent SEC filings of CareDx Inc

View All Filings
Date Filed Form Type Document
Apr 10, 2024
4
Insider Trading
Apr 09, 2024
4/A
Insider Trading
Apr 09, 2024
4/A
Insider Trading
Apr 08, 2024
4
Insider Trading
Apr 08, 2024
4
Insider Trading
Mar 11, 2024
8-K
Current Report
Mar 01, 2024
POS AM
POS AM
Feb 28, 2024
10-K
Annual Report
Feb 28, 2024
8-K
Current Report
Feb 28, 2024
POSASR
POSASR

Peers (Alternatives to CareDx Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
177.3B
23.9B
-3.91% -4.78%
37.37
7.42
-10.33% -33.23%
41.1B
6.7B
-4.92% 0.73%
33.25
6.1
-2.81% -6.58%
40.8B
3.7B
-7.22% 1.87%
48.33
11.16
8.72% 24.44%
14.2B
9.3B
0.30% -9.60%
16.68
1.54
-6.38% -9.73%
12.1B
4.1B
-8.95% 15.76%
25.51
2.93
3.86% -2.39%
11.9B
1.9B
-2.43% 101.48%
42.11
6.31
29.17% 15.26%
11.9B
2.5B
13.24% -2.16%
-58.11
4.75
19.93% 67.26%
10.9B
1.1B
0.99% 75.89%
-25.11
10.08
31.99% 20.63%
MID-CAP
2.6B
929.2M
-20.88% -25.40%
1.7K
2.8
28.93% 111.61%
2.1B
563.9M
-3.78% -30.33%
-4.33
3.68
25.45% 26.76%
SMALL-CAP
425.1M
280.3M
-19.03% -7.55%
-2.23
1.52
-12.89% -148.37%
86.5M
31.2M
4.27% -86.20%
-0.98
2.77
5.03% -1.81%
41.5M
9.2M
-6.67% -36.96%
-2.48
4.53
11.85% 44.12%
6.1M
9.0M
-2.70% -65.71%
-0.85
0.68
-53.31% 2.21%
183.8K
25.9M
-50.00% -94.83%
-0.01
0.01
-57.78% -93.11%

CareDx Inc News

Latest updates
Defense World12 Apr 202408:15 am
MarketBeat09 Apr 202404:14 pm
Yahoo Finance01 Apr 202407:00 am
Yahoo Finance29 Feb 202408:00 am
Seeking Alpha28 Feb 202408:00 am

CareDx Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-2.4%65,569,00067,192,00070,301,00077,262,00082,384,00079,359,00080,634,00079,416,00079,220,00075,589,00074,188,00067,400,00058,644,00053,369,00041,801,00038,380,00035,821,00033,811,00031,454,00025,982,00023,509,000
Cost Of Revenue---------------15,025,00012,392,00012,716,00011,494,00011,512,0009,733,00010,509,000
Gross Profit---------------26,776,00025,988,00023,105,00022,317,00019,942,00016,249,00013,000,000
Operating Expenses96.1%188,201,00095,975,00097,925,000101,586,000101,504,00096,698,000102,353,00098,469,00094,619,00084,316,00078,930,00068,258,00061,711,00056,276,00052,604,00044,131,00051,988,50040,558,00026,786,00021,645,00045,210,000
  S&GA Expenses8.3%19,999,00018,474,00021,630,00023,231,00023,668,00022,261,00026,950,00023,148,00020,824,00021,370,00019,599,00015,452,00016,131,00013,870,00012,134,00011,723,00010,267,00011,058,00010,644,0006,925,0005,754,000
  R&D Expenses-3.8%18,276,00019,000,00020,233,00024,357,00023,570,00022,306,00022,632,00021,880,00022,046,00019,439,00019,036,00016,004,00013,325,00012,474,00013,129,00010,013,0008,946,0008,521,0007,630,0005,614,0003,782,000
EBITDA Margin-Infinity%-0.63--0.23-0.21-0.20-0.20-0.19-0.13-0.08-0.04-0.01-0.03-0.07--------
Income Taxes306.3%165,000-80,000-68,000124,000173,000267,000-49,000-12,000-894,500-200,000-100,000-263,000-203,500-200,000-300,000-300,000-228,500-900,000-220,000-606,000-336,500
Earnings Before Taxes-400.5%-117,932,000-23,565,000-25,021,000-23,625,000-18,156,000-16,672,000-21,746,000-19,660,000-17,052,000-12,059,000-2,027,000-950,000-3,686,000-3,053,000-6,888,000-6,123,000-4,981,000-2,762,000-8,067,000-8,137,000-4,094,000
EBT Margin-123.0%-0.68-0.30-0.27-0.25-0.24-0.24-0.22-0.16-0.11-0.07-0.04-0.07---------
Net Income-402.9%-118,097,000-23,485,000-24,953,000-23,749,000-18,329,000-16,939,000-21,697,000-19,648,000-16,151,000-11,897,000-1,927,000-687,000-3,515,000-2,818,000-6,558,000-5,823,000-4,777,000-1,813,000-7,847,000-7,531,000-3,755,000
Net Income Margin-122.8%-0.68-0.30-0.27-0.25-0.24-0.23-0.22-0.16-0.10-0.07-0.04-0.06---------
Free Cashflow17.7%-8,381,000-10,179,000-4,122,000-2,952,0003,562,000-10,702,000-7,500,000-25,091,000543,000-3,241,0006,950,000-34,880,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-6.9%467501515528543545541547567563557541369354345157152145143128131
  Current Assets-9.1%31434536137138838840441143344544143927325925266.0072.0068.0068.0078.0081.00
    Cash Equivalents8.2%82.0076.0088.0075.0090.0083.0016717234835333630913521421132.0038.0041.0044.0058.0065.00
  Inventory8.3%19.0018.0019.0018.0019.0018.0019.0018.0017.0019.0015.0014.0010.0010.009.007.006.006.005.005.005.00
  Net PPE----------19.0014.0011.0011.0010.007.006.004.004.004.004.004.00
  Goodwill0.3%40.0040.0040.0040.0038.0038.0037.0037.0037.0026.0026.0026.0024.0024.0024.0024.0024.0024.0023.00--
Liabilities92.0%20510711010811210898.0089.0010191.0078.0070.0091.0085.0084.0055.0053.0047.0050.0032.0035.00
  Current Liabilities7.4%78.0073.0074.0072.0076.0070.0078.0067.0077.0070.0056.0046.0069.0062.0057.0028.0035.0031.0029.0016.0020.00
  Long Term Debt----------------------
    LT Debt, Current----------------------
    LT Debt, Non Current----------------------
Shareholder's Equity-33.7%26139440542043143744445846647248047227826926110199.0098.0093.0096.0096.00
  Retained Earnings-27.0%-678-534-509-484-460-441-424-402-383-367-355-353-352-349-346-339-333-329-327-319-311
  Additional Paid-In Capital1.0%947937924912899887875865854843838828632622612448438432425420412
Shares Outstanding-4.9%52.0054.0054.0054.0054.0053.0053.0053.0052.0053.0052.0051.00---------
Minority Interest----------------------
Float---437---1,100---4,600---1,700---1,502--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations17.7%-8,381-10,179-4996717,185-7,079-3,877-21,4684,1663829,788-33,6307,1815,20724,098-3,055-1,0836053,576-5,8671,998
  Share Based Compensation-21.4%9,96112,67112,70013,75412,12611,20012,59310,6349,49810,6389,3986,5475,9776,7486,4174,2595,4075,9654,9926,0532,060
Cashflow From Investing2861.5%41,367-1,49815,348-14,7712,475-75,735790-156,032-7,78220,20216,21319,079-90,474-4,236-3,980-1,704-1,342-3,515-17,179-543-960
Cashflow From Financing-107408.0%-26,877-25.00-1,566-1,138-2,372-1,031-1,997865-834-3,133381189,2283,9641,224158,696-73582.00746-272-68837,312
  Buy Backs3090.4%25,97081467.00690642--------698--------

CDNA Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues [Abstract]   
Total revenue$ 280,324$ 321,793$ 296,397
Operating expenses:   
Research and development81,86690,38876,525
Sales and marketing83,33496,02777,245
General and administrative117,868100,39774,964
Restructuring costs2,32000
Litigation expense (Note 17)96,30000
Total operating expenses483,687399,024326,123
Loss from operations(203,363)(77,231)(29,726)
Other income (expense):   
Interest income, net11,8673,762160
Change in estimated fair value of common stock warrant liability10107106
Other income (expense), net1,343(2,872)(2,628)
Total other income (expense)13,220997(2,362)
Loss before income taxes(190,143)(76,234)(32,088)
Income tax (expense) benefit(141)(379)1,426
Net loss$ (190,284)$ (76,613)$ (30,662)
Net loss per share (Note 3):   
Basic (in dollars per share)$ (3.54)$ (1.44)$ (0.59)
Diluted (in dollars per share)$ (3.54)$ (1.44)$ (0.59)
Weighted-average shares used to compute net loss per share:   
Basic (in shares)53,764,70553,321,62552,241,076
Diluted (in shares)53,764,70553,321,62552,241,076
Testing services revenue   
Revenues [Abstract]   
Total revenue$ 209,685$ 263,748$ 259,285
Operating expenses:   
Cost of testing services, product, patient and digital solutions57,64272,28671,251
Product revenue   
Revenues [Abstract]   
Total revenue33,51729,25126,832
Operating expenses:   
Cost of testing services, product, patient and digital solutions18,37917,63918,930
Patient and digital solutions   
Revenues [Abstract]   
Total revenue37,12228,79410,280
Operating expenses:   
Cost of testing services, product, patient and digital solutions$ 25,978$ 22,287$ 7,208

CDNA Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 82,197,000$ 89,921,000
Marketable securities153,221,000203,168,000
Accounts receivable51,061,00066,312,000
Inventory19,471,00019,232,000
Prepaid and other current assets7,763,0009,216,000
Total current assets313,713,000387,849,000
Property and equipment, net35,246,00035,529,000
Operating leases right-of-use assets29,891,00034,689,000
Intangible assets, net45,701,00043,051,000
Goodwill40,336,00037,523,000
Restricted cash586,000522,000
Other assets1,353,0003,828,000
Total assets466,826,000542,991,000
Current liabilities:  
Accounts payable12,872,0009,942,000
Accrued compensation19,703,00016,902,000
Accrued and other liabilities45,497,00049,131,000
Total current liabilities78,072,00075,975,000
Deferred tax liability136,0000
Common stock warrant liability032,000
Deferred payments for intangible assets2,461,0002,418,000
Operating lease liability, less current portion28,278,00033,406,000
Other liabilities96,551,000249,000
Total liabilities205,498,000112,080,000
Commitments and contingencies (Note 9)
Stockholders’ equity:  
Preferred stock: $0.001 par value; 10,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 202200
Common stock: $0.001 par value; 100,000,000 shares authorized at December 31, 2023 and 2022; 51,503,377 shares issued and outstanding at December 31, 2023; 53,583,301 shares issued and 53,533,250 shares outstanding at December 31, 202249,00052,000
Additional paid-in capital946,511,000898,806,000
Accumulated other comprehensive loss(6,963,000)(7,503,000)
Accumulated deficit(678,269,000)(460,444,000)
Total stockholders’ equity261,328,000430,911,000
Total liabilities and stockholders’ equity$ 466,826,000$ 542,991,000
Common stock, shares outstanding (in shares)51,503,37753,533,250
CDNA
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEcaredx.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES727

CareDx Inc Frequently Asked Questions


What is the ticker symbol for CareDx Inc? What does CDNA stand for in stocks?

CDNA is the stock ticker symbol of CareDx Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CareDx Inc (CDNA)?

As of Mon Apr 15 2024, market cap of CareDx Inc is 425.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CDNA stock?

You can check CDNA's fair value in chart for subscribers.

What is the fair value of CDNA stock?

You can check CDNA's fair value in chart for subscribers. The fair value of CareDx Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CareDx Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CDNA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CareDx Inc a good stock to buy?

The fair value guage provides a quick view whether CDNA is over valued or under valued. Whether CareDx Inc is cheap or expensive depends on the assumptions which impact CareDx Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CDNA.

What is CareDx Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, CDNA's PE ratio (Price to Earnings) is -2.23 and Price to Sales (PS) ratio is 1.52. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CDNA PE ratio will change depending on the future growth rate expectations of investors.